WO1999053834A1 - Determining cardiac output - Google Patents

Determining cardiac output Download PDF

Info

Publication number
WO1999053834A1
WO1999053834A1 PCT/US1999/008539 US9908539W WO9953834A1 WO 1999053834 A1 WO1999053834 A1 WO 1999053834A1 US 9908539 W US9908539 W US 9908539W WO 9953834 A1 WO9953834 A1 WO 9953834A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxygen
location
cardiac output
gas
oxygen saturation
Prior art date
Application number
PCT/US1999/008539
Other languages
French (fr)
Inventor
Babak Kasravi
John P. Boehmer
Urs Leuenberger
Original Assignee
The Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Penn State Research Foundation filed Critical The Penn State Research Foundation
Publication of WO1999053834A1 publication Critical patent/WO1999053834A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026Measuring blood flow
    • A61B5/0275Measuring blood flow using tracers, e.g. dye dilution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026Measuring blood flow
    • A61B5/029Measuring or recording blood output from the heart, e.g. minute volume

Definitions

  • the invention relates to medical instrumentation. Particularly, the invention relates to a system and method for determining cardiac output. BACKGROUND OF THE INVENTION
  • Indicator-dilution techniques entail injection of an inert substance as
  • the injection site is usually a systemic vein or the
  • Indicator-dilution techniques for measuring cardiac output are based on the
  • Indicator-dilution curves can be generated from
  • flow of blood in a given period of time is equal to the amount of substance entering the stream of flow in the same period of time divided by the difference between concentrations of the substance in the blood upstream and downstream from its point of entry into the circulation.
  • Thermodilution is one of the most recent commonly utilized applications of the indicator-dilution method.
  • Thermodilution requires an invasive procedure to obtain central venous access for insertion of a balloon floatation pulmonary artery catheter.
  • the indicator which is cold saline
  • a thermistor is a device to measure and record temperature. The thermistor detects temperature changes generated by injection of the cold saline indicator and produces indicator-dilution curves. Cardiac output is then determined from the curves.
  • Thermodilution procedures are invasive procedures requiring central venous access and injection via a catheter. Complications associated with such procedures include pneumothorax, air embolism and dysrhythmia, infections, thromboembolism and rupture of the pulmonary artery. Goldenheim et al., Cardiopulmonary Monitoring
  • the present invention provides a noninvasive, risk free, economically feasible, time efficient and accurate means for monitoring cardiac output at the bedside or in an outpatient setting.
  • the invention relates to a noninvasive method for monitoring cardiac output.
  • a respiratory gas is administered for inhalation into a living body at a first location.
  • Circulation time (CT) is determined as a measure of cardiac output at a second location or buildup time (T b ) ' s determined as a measure of cardiac output at the second location.
  • CT is time between administration of the respiratory gas and detecting of an increase peak in concentration of the gas at the second location.
  • T b is time between first detecting of an increase in the respiratory gas at the second location to detecting an increase peak in concentration of the gas at the second location.
  • the invention relates to a system for determining cardiac output in a living body.
  • the system comprises a source to administer a respiratory gas for inhalation into the living body at a first location, a device to measure oxygen saturation of blood by means of adsorption of optical radiation through living tissue connected to the living body at a location respiratorily downstream from the first location and a processor that calculates circulation time (CT) or buildup time (T b ) from the device measurements to determine cardiac output
  • CT circulation time
  • T b buildup time
  • FIG. 1 is an oxygen saturation (%) verses time (sec.) plot
  • FIG. 2 is a plot comparing cardiac output as measured by an invasive methods to the inverse Lung to Finger Circulation Time (LFCT);
  • LFCT inverse Lung to Finger Circulation Time
  • FIG. 3 is a plot comparing cardiac output as measured by an invasive methods to the to the inverse Buildup Time (T b ) method
  • FIG. 4 is a plot comparing cardiac output as measured by an invasive methods to the inverse Lung to Finger Circulation Time (LFCT);
  • FIG. 5 is a plot comparing cardiac output as measured by an invasive methods to the inverse Buildup Time (T b ) method
  • FIG. 6 is an oxygen saturation (%) verses time (sec.) plot (pulse administration of oxygen);
  • FIG. 7 is an oxygen saturation (%) verses time (sec.) plot (hypoxic gas administration followed by administration of oxygen).
  • FIG. 8 is an oxygen saturation (%) verses time (sec.) plot (hypoxic gas administration followed by pulse administration of oxygen).
  • Indicator-dilution techniques entail injection of an inert substance, the indicator, into the circulation and sampling of the indicator downstream from the injection site.
  • the lung and alveolar capillaries are used as an injection site and respiratory gas, preferably oxygen as an indicator. Change in oxygen saturation is monitored by an oximeter as a mode of detection of the indicator.
  • the transmission of light at a wavelength is a function of thickness, color and
  • a pulse oximeter measures light transmission in pulsatile arterial blood and can be used to monitor arterial blood hemoglobin oxygen saturation.
  • the pulse oximeter uses two different monochromatic light beams, which are emitted by
  • ALEDs ⁇ light emitting diodes
  • the pulse oximeter includes an oxygen saturation sensing probe which is arranged to be secured
  • the probe has the form of a clip including both
  • the probe is arranged so that the single light detector receives the light of both LEDs after the light has passed through the patient's body.
  • the light of both LEDs is attenuated by static and dynamic absorbers on its path through the patient's body to the light detector.
  • the quantity of arterial blood varies with time synchronously with a patient's heartbeat and represents the only dynamic absorber during the pulse period. All other absorbers, such as skin, tissue or bone, are not time-variant.
  • the light detector which may be a photodiode, receives attenuated light of each
  • Signals produced by the diode in response to the light are amplified, low pass filtered, converted from analog to digital and further processed by a microprocessor.
  • a pulse finding algorithm analyses the received signals, which are called spectrophotometric signals to identify and determine pulse.
  • the microprocessor determines diastolic and systolic values of the spectrophotometric signals and derives relative absorption ratios.
  • noninvasive indicator-dilution test namely resaturation curves to detect rate of change in arterial oxygen saturation in an exercising subject during breathing of various concentrations of oxygen.
  • a mild hypoxia is induced in the subject followed by administration of 100% oxygen to abruptly cause resaturation of blood hemoglobin.
  • Changes in arterial oxygen saturation (SaO 2 ) are recorded with an oximeter.
  • Goodenday et al determines a time constant, ⁇ as the time required for SaO 2 to rise 63 percent of the distance to its final equilibrium value. Goodenday et al also defines a
  • HR heart rate
  • cardiac output is determined with a system that includes a reparatory gas source to provide an increased gas concentration for inhalation into a living body at a first location and a device to measure optical radiation through a living body at a location respiratorily downstream from the first location.
  • the respiratory gas is oxygen and the device to measure optical radiation is an oximeter.
  • a change in inspired oxygen concentration leads to detection of a
  • CT computed tomography
  • a first method includes continuous monitoring of oxygen saturation (SaO 2 ) in a subject for approximately 1-2 minutes while the subject is lying still in a supine or sitting position to establish a baseline oxygen saturation level. Then a higher concentration of oxygen or 100% supplemental oxygen is administered via an oxygen mask, a partial rebreathable mask or a non-rebreather mask.
  • the gas can also be administered by any type of face mask, nasal cannula, through an endotracheal tube, by means of an oxygen tent or the like.
  • 100% oxygen can be administered through the endotracheal tube via the ventilator.
  • the subject s oxygen saturation (ASaO 2 A) is recorded by an on-line computer and CT and T b are measured and determined by a computer.
  • the subject is administered a pulse of supplemental oxygen in the form of a known number of breaths of 100% oxygen or a known volume of 100% oxygen followed by a return to room air breathing.
  • Subjects with low baseline oxygen saturation exhibit a high signal to noise ratio and an increase in dynamic range in the first portion of the oxygen saturation versus
  • the signal is augmented by administering a few breaths of hypoxic gas to decrease the subject's baseline SaO 2 followed by the administration of continuous 100
  • hypoxic gas is a gas with decreased oxygen level. Hypoxic gas mixtures are typically made using a combination of oxygen and nitrogen. Room air contains approximately 21 % oxygen with nitrogen as the majority of the remaining gas. A mixture that contains less than 21 % oxygen is a hypoxic gas mixture. Typically, a gas mixture containing 10% oxygen is used in experiments involving human subjects. In one embodiment of the present invention, a subject receives a pulse of 100% supplemental oxygen following the hypoxic gas administration.
  • the subjects medical profiles included dilated cardiomyopathy, aortic stenosis, status post orthotopic cardiac transplant, unstable angina, coronary artery disease, atrial fibrillation, renal failure, diabetes mellitus and congestive heart failure. Two of the subjects already had an indwelling Swan Ganz catheter and 20 were studied immediately before or after right heart catheterization
  • Cardiac output was measured 3-5 times by the thermodilution method.
  • a pulmonary artery balloon flotation catheter (Baxter Corporation) was placed in either the right or left pulmonary artery under fluoroscopic guidance. Thermodilution was
  • Cardiac output was then monitored by the system of the invention.
  • a finger probe connected to an Ohmeda 3740 pulse oximeter was placed on either the index or the middle finger of the subject lying supine in bed. Oxygen saturation was recorded continuously via an on-line computer at 25 Hz per channel. A second channel was used
  • the marking channel is a recording with two levels - on and off.
  • the marking channel was on when oxygen was administered and off when discontinued to provide a high voltage mark at onset of administration of 100% oxygen thereby generating a vertical line on the oxygen saturation plot to serve as a designation of time of onset of oxygen administration.
  • the subject's baseline oxygen saturation was recorded for approximately one minute. Three deep breaths of 100% oxygen via a nonrebreather oxygen mask were then administered and the subject's oxygen
  • T b is illustrated in FIG. 1, which is an oxygen saturation (%) verses time (sec.) plot as recorded by an on-line computer.
  • the shaded area depicts time interval for administration of three breaths of 100% oxygen.
  • the LFCT of oxygen was measured from the onset of 100% oxygen administration to peak in oxygen saturation.
  • T b was measured from the onset of rise in oxygen saturation to the peak in oxygen saturation.
  • Cardiac output values obtained by the thermodilution method were compared with the inverse of LFCT and T b values by linear regression analysis for paired data.
  • FIG. 2 is a comparison of cardiac output as measured by thermodilution to inverse LFCT in 22 subjects.
  • FIG. 3 is a comparison of cardiac output as measured by thermodilution to inverse T b in 22 subjects.
  • FIG. 4 is a comparison of cardiac output as measured by thermodilution to inverse LFCT in 13 subjects with baseline oxygen saturation less than or equal to the median baseline oxygen saturation (95%).
  • FIG. 5 is a comparison of cardiac output as measured by invasive methods to inverse LFCT in 9 subjects with baseline oxygen saturation greater than the median baseline oxygen saturation (95%).
  • the subject received a pulse of 100% supplemental oxygen in the form of a known number of breaths of oxygen via a non- rebreather mask or a known volume of oxygen followed by room air breathing.
  • a few breaths of hypoxic gas were first administered to
  • hypoxic gas was first administered followed by a pulse of 100% supplemental oxygen via a non-rebreather mask.
  • R is the correlation coefficient, a statistical value to describe how well the data are represented by an equation of a straight line.
  • a group of values that form a perfect line have an R value of 1.
  • a group of values that are randomly distributed have an R value of 0.
  • the p value is a statistical representation of the probability that there is some relationship
  • the p value represents the probability of what is referred to as the null hypothesis, or that two variables under study are not related to one another. In the present studies, p was less than 0.001. In other words, there is greater than a 99.9% chance that the null hypothesis is not applicable and the two variables are related to one another.
  • T b is safe due to the use of oxygen as the indicator and its noninvasive nature. Furthermore, these determinations are inexpensive and practical since they utilizes detection by oximeters, which are commonly found in the hospital and clinical settings. Other modifications of the present invention will occur to those skilled in the art subsequent to a review of the present application. These modifications and equivalents thereof are intended to be included within the scope of this invention.

Abstract

Cardiac output is determined by administering a respiratory gas for inhalation into a living body at a first location. Adsorption of optical radiation is then measured through living tissue at a location respiratorily downstream from the first location to determine an increase in circulated oxygen as a result of the increased oxygen. A system for determining cardiac output in a living body includes a source to administer a respiratory gas for inhalation into the living body at a first location and an oximeter connected to the living body at a location respiratorily downstream from the first location. The oximeter measures pulse rate and oxygen saturation of blood by means of adsorption of optical radiation through living tissue. A processor calculates circulation time (CT) or buildup time (Tb) from the device measurements to determine cardiac output.

Description

TITLE
DETERMINING CARDIAC OUTPUT
FIELD OF THE INVENTION
The invention relates to medical instrumentation. Particularly, the invention relates to a system and method for determining cardiac output. BACKGROUND OF THE INVENTION
Measurement of cardiac output is important in the evaluation, treatment and
follow up of critically ill patients. Indicator-dilution methods are often used to measure
cardiac output. Indicator-dilution techniques entail injection of an inert substance as
an indicator into a circulatory system of the body and sampling of the indicator
downstream from the injection site. The injection site is usually a systemic vein or the
right side of the heart and the sampling site is often the pulmonary artery or a systemic
artery, far enough downstream to allow adequate mixing.
Indicator-dilution techniques for measuring cardiac output are based on the
assumption that after injection of a quantity of an indicator into the circulation, the
indicator appears and disappears from any downstream location in a manner dependant
on cardiac output. With high cardiac output, the indicator rapidly appears and washes
out quickly at a downstream location. Indicator-dilution curves can be generated from
serial or continuous measurement of the indicator concentration. Cardiac output then
can be measured using the area under an indicator-dilution curves. Braunwald, Heart
Disease, Chapter 6, pages 191-193, 5th Edition (1997). The Fick principle quantitizes
this assumption by further assuming that the rate at which oxygen is consumed is a
function of the rate of blood flow times the rate of oxygen pickup of red blood cells and
that flow of blood in a given period of time is equal to the amount of substance entering the stream of flow in the same period of time divided by the difference between concentrations of the substance in the blood upstream and downstream from its point of entry into the circulation.
Thermodilution is one of the most recent commonly utilized applications of the indicator-dilution method. Thermodilution requires an invasive procedure to obtain central venous access for insertion of a balloon floatation pulmonary artery catheter.
The indicator, which is cold saline, is injected via the proximal port of the catheter into the right heart ventricle. A thermistor at the tip of the catheter positioned in the pulmonary artery, is the detector. A thermistor is a device to measure and record temperature. The thermistor detects temperature changes generated by injection of the cold saline indicator and produces indicator-dilution curves. Cardiac output is then determined from the curves.
Thermodilution procedures are invasive procedures requiring central venous access and injection via a catheter. Complications associated with such procedures include pneumothorax, air embolism and dysrhythmia, infections, thromboembolism and rupture of the pulmonary artery. Goldenheim et al., Cardiopulmonary Monitoring
of Critically 111 Patients, The New England Journal of Medicine, Sept. 20, 1984, pp.776-780. Several noninvasive techniques for estimating cardiac output have been developed, such as carbon dioxide rebreathing, electrical bioimpedance, Doppler ultrasonography and acetylene rebreathing. None is as reliable as the invasive standard procedure - thermodilution. Hence, there is a need for a noninvasive and reliable method for monitoring cardiac output. The present invention provides a noninvasive, risk free, economically feasible, time efficient and accurate means for monitoring cardiac output at the bedside or in an outpatient setting. SUMMARY OF THE INVENTION
The invention relates to a noninvasive method for monitoring cardiac output. In the method, a respiratory gas is administered for inhalation into a living body at a first location. Circulation time (CT) is determined as a measure of cardiac output at a second location or buildup time (Tb) 's determined as a measure of cardiac output at the second location. CT is time between administration of the respiratory gas and detecting of an increase peak in concentration of the gas at the second location. Tb is time between first detecting of an increase in the respiratory gas at the second location to detecting an increase peak in concentration of the gas at the second location In another aspect, the invention relates to a system for determining cardiac output in a living body. The system comprises a source to administer a respiratory gas for inhalation into the living body at a first location, a device to measure oxygen saturation of blood by means of adsorption of optical radiation through living tissue connected to the living body at a location respiratorily downstream from the first location and a processor that calculates circulation time (CT) or buildup time (Tb) from the device measurements to determine cardiac output
The invention is more readily understood and appreciated by reference to the following Drawings.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is an oxygen saturation (%) verses time (sec.) plot;
FIG. 2 is a plot comparing cardiac output as measured by an invasive methods to the inverse Lung to Finger Circulation Time (LFCT);
FIG. 3 is a plot comparing cardiac output as measured by an invasive methods to the to the inverse Buildup Time (Tb) method; FIG. 4 is a plot comparing cardiac output as measured by an invasive methods to the inverse Lung to Finger Circulation Time (LFCT);
FIG. 5 is a plot comparing cardiac output as measured by an invasive methods to the inverse Buildup Time (Tb) method;
FIG. 6 is an oxygen saturation (%) verses time (sec.) plot (pulse administration of oxygen);
FIG. 7 is an oxygen saturation (%) verses time (sec.) plot (hypoxic gas administration followed by administration of oxygen); and
FIG. 8 is an oxygen saturation (%) verses time (sec.) plot (hypoxic gas administration followed by pulse administration of oxygen). DETAILED DESCRIPTION OF THE INVENTION
Indicator-dilution techniques entail injection of an inert substance, the indicator, into the circulation and sampling of the indicator downstream from the injection site.
In the present invention, the lung and alveolar capillaries are used as an injection site and respiratory gas, preferably oxygen as an indicator. Change in oxygen saturation is monitored by an oximeter as a mode of detection of the indicator.
The transmission of light at a wavelength is a function of thickness, color and
structure of skin, flesh, bone, blood and other material through which the light passes. This attenuation in transmission has a logarithmic characteristic in accordance with the Lambert-Beers Law. A pulse oximeter measures light transmission in pulsatile arterial blood and can be used to monitor arterial blood hemoglobin oxygen saturation. The pulse oximeter uses two different monochromatic light beams, which are emitted by
light emitting diodes (ALEDs≡); one LED emitting light in the red wavelength range
of about 645 nm, another LED emitting light in the infrared wavelength range of about 940 nm. Both beams are transmitted through an area of a patient's body. The pulse oximeter includes an oxygen saturation sensing probe which is arranged to be secured
to a subject=s finger or ear. Usually, the probe has the form of a clip including both
LEDs and a light detector. The probe is arranged so that the single light detector receives the light of both LEDs after the light has passed through the patient's body. The light of both LEDs is attenuated by static and dynamic absorbers on its path through the patient's body to the light detector. The quantity of arterial blood varies with time synchronously with a patient's heartbeat and represents the only dynamic absorber during the pulse period. All other absorbers, such as skin, tissue or bone, are not time-variant.
The light detector, which may be a photodiode, receives attenuated light of each
wavelength. Signals produced by the diode in response to the light, are amplified, low pass filtered, converted from analog to digital and further processed by a microprocessor. A pulse finding algorithm analyses the received signals, which are called spectrophotometric signals to identify and determine pulse. After identifying pulse, the microprocessor determines diastolic and systolic values of the spectrophotometric signals and derives relative absorption ratios. The microprocessor
computes arterial oxygen saturation from the relative absorption ratio using calibration data and extinction coefficients from the absorption spectrum of hemoglobin and oxyhemoglobin at the appropriate wavelengths.
Goodenday et al., Noninvasive Measurement of Cardiac Function during Exercise, Using Resaturation Curves, Chest 1976, 70, 6, pages 732-739, discloses a
noninvasive indicator-dilution test, namely resaturation curves to detect rate of change in arterial oxygen saturation in an exercising subject during breathing of various concentrations of oxygen. A mild hypoxia is induced in the subject followed by administration of 100% oxygen to abruptly cause resaturation of blood hemoglobin. Changes in arterial oxygen saturation (SaO2) are recorded with an oximeter.
Goodenday et al determines a time constant, τ as the time required for SaO2 to rise 63 percent of the distance to its final equilibrium value. Goodenday et al also defines a
clearance function SV/V that is inversely proportionate to the quotient (τ)(HR) where
HR is heart rate. Goodenday et al reports a study that compared normal subjects with
patients with cardiac valve disease and concluded that τ decreases with increasing cardiac output while the clearance function (SV/V) decreases with impairment of cardiac function during exercise.
According to the present invention, cardiac output is determined with a system that includes a reparatory gas source to provide an increased gas concentration for inhalation into a living body at a first location and a device to measure optical radiation through a living body at a location respiratorily downstream from the first location. Preferably, the respiratory gas is oxygen and the device to measure optical radiation is an oximeter. A change in inspired oxygen concentration leads to detection of a
change in oxygen saturation measured by the pulse oximeter after a period of time delay. This time delay between administration of the oxygen indicator into the lungs and its detection in the systemic capillaries, namely the circulation time, is then measured. This measurement (CT) has been found to correlate to cardiac output as measured by the thermodilution method. Buildup Time (Tb) is the time from appearance of an indicator to its peak concentration. According to the present invention, this factor has also been found to correlate to cardiac output as measured by the thermodilution method. CT and Tb can be determined by any one of several methods that are embraced within the present invention. A first method includes continuous monitoring of oxygen saturation (SaO2) in a subject for approximately 1-2 minutes while the subject is lying still in a supine or sitting position to establish a baseline oxygen saturation level. Then a higher concentration of oxygen or 100% supplemental oxygen is administered via an oxygen mask, a partial rebreathable mask or a non-rebreather mask. The gas can also be administered by any type of face mask, nasal cannula, through an endotracheal tube, by means of an oxygen tent or the like. Thus for example, if a patient is on a ventilator, 100% oxygen can be administered through the endotracheal tube via the ventilator.
The subject=s oxygen saturation (ASaO2 A) is recorded by an on-line computer and CT and Tb are measured and determined by a computer. In another embodiment, the subject is administered a pulse of supplemental oxygen in the form of a known number of breaths of 100% oxygen or a known volume of 100% oxygen followed by a return to room air breathing.
Subjects with low baseline oxygen saturation exhibit a high signal to noise ratio and an increase in dynamic range in the first portion of the oxygen saturation versus
time curve thus making measurement of CT and Tb easier and more accurate. In another method, the signal is augmented by administering a few breaths of hypoxic gas to decrease the subject's baseline SaO2 followed by the administration of continuous 100
% supplemental oxygen via a non-rebreather mask. An hypoxic gas is a gas with decreased oxygen level. Hypoxic gas mixtures are typically made using a combination of oxygen and nitrogen. Room air contains approximately 21 % oxygen with nitrogen as the majority of the remaining gas. A mixture that contains less than 21 % oxygen is a hypoxic gas mixture. Typically, a gas mixture containing 10% oxygen is used in experiments involving human subjects. In one embodiment of the present invention, a subject receives a pulse of 100% supplemental oxygen following the hypoxic gas administration.
The invention is illustrated by the following examples.
EXAMPLES
Studies were conducted to measure cardiac output of various subjects to compare the methods of the invention with the thermodilution method.
Fourteen male and eight female subjects who were undergoing diagnostic right
heart catheterization for clinical indications participated in the studies. The subjects=
ages ranged between 21-81 years with a mean of 51.9V 14.3, their weights ranged
between 61-123 kg with a mean of 90.1V 20.5 and their heights ranged between 152-
185 cm with a mean of 169.8V9.2. The subjects= medical profiles included dilated cardiomyopathy, aortic stenosis, status post orthotopic cardiac transplant, unstable angina, coronary artery disease, atrial fibrillation, renal failure, diabetes mellitus and congestive heart failure. Two of the subjects already had an indwelling Swan Ganz catheter and 20 were studied immediately before or after right heart catheterization
Cardiac output was measured 3-5 times by the thermodilution method. A pulmonary artery balloon flotation catheter (Baxter Corporation) was placed in either the right or left pulmonary artery under fluoroscopic guidance. Thermodilution was
performed with the use of a cardiac output computer (Baxter Corporation) connected to a thermister at the tip of the pulmonary artery catheter. For each measurement, 10 cc of room temperature normal saline was injected into the proximal port of the pulmonary artery catheter. The result reported by a cardiac output computer was recorded.
Three measurements within 10% of the mean or average of five measurements was used as an acceptable value for cardiac output. Nine patients had moderate to severe tricuspid regurgitation. Since cardiac output measurements by thermodilution method may not be accurate in the presence of tricuspid regurgitation, the Fick method of estimating cardiac output utilizing measured pulmonary artery saturation and direct arterial saturation was used for these subjects. The Fick method of determining cardiac output was performed using standard methods of measuring oxygen content of arterial mixed venous blood and oxygen consumption either measured directly or estimated based on the patient's demographics. Cardiac output was calculated as oxygen consumption divided by arterial-venous oxygen contact difference.
Cardiac output was then monitored by the system of the invention. A finger probe connected to an Ohmeda 3740 pulse oximeter was placed on either the index or the middle finger of the subject lying supine in bed. Oxygen saturation was recorded continuously via an on-line computer at 25 Hz per channel. A second channel was used
as a marking channel. The marking channel is a recording with two levels - on and off.
The marking channel was on when oxygen was administered and off when discontinued to provide a high voltage mark at onset of administration of 100% oxygen thereby generating a vertical line on the oxygen saturation plot to serve as a designation of time of onset of oxygen administration. The subject's baseline oxygen saturation was recorded for approximately one minute. Three deep breaths of 100% oxygen via a nonrebreather oxygen mask were then administered and the subject's oxygen
saturation was recorded for another 3-4 minutes. The initiation of the first breath of oxygen was labeled via the marking channel on an oxygen saturation plot. This protocol was repeated 3-5 times and a mean of the values was calculated. Following administration of 100% oxygen, the subject's oxygen saturation was monitored by finger pulse oximetry. The oxygen saturation was observed to rise, peak and return to baseline, as in other indictor dilution methods. See FIG. 1.
Two different components of oxygen saturation curves were blindly analyzed.
First, the time interval between initiation of the first breath of 100% oxygen and the peak in the oxygen saturation plot (CT) was measured. In these Examples, LFCT is
CT for ALung to Finger Circulation Time. Second, the time from onset of a rise from
baseline in the oxygen saturation curve to peak oxygen saturation was measured. This
component is Tb. Tb is illustrated in FIG. 1, which is an oxygen saturation (%) verses time (sec.) plot as recorded by an on-line computer. The shaded area depicts time interval for administration of three breaths of 100% oxygen. The LFCT of oxygen was measured from the onset of 100% oxygen administration to peak in oxygen saturation. Tb was measured from the onset of rise in oxygen saturation to the peak in oxygen saturation.
Cardiac output values obtained by the thermodilution method were compared with the inverse of LFCT and Tb values by linear regression analysis for paired data.
Regression analysis was done using software package SPSS 7.5.1 for Windows ™. The statistical analysis included calculation of R or coefficient of R probability values and standard estimate of error. All values for measured parameters in the studies were
expressed as mean V standard deviation.
10 In the drawings, FIG. 2 is a comparison of cardiac output as measured by thermodilution to inverse LFCT in 22 subjects. FIG. 3 is a comparison of cardiac output as measured by thermodilution to inverse Tb in 22 subjects.
FIG. 4 is a comparison of cardiac output as measured by thermodilution to inverse LFCT in 13 subjects with baseline oxygen saturation less than or equal to the median baseline oxygen saturation (95%). FIG. 5 is a comparison of cardiac output as measured by invasive methods to inverse LFCT in 9 subjects with baseline oxygen saturation greater than the median baseline oxygen saturation (95%).
In the study illustrated in FIG. 6, the subject received a pulse of 100% supplemental oxygen in the form of a known number of breaths of oxygen via a non- rebreather mask or a known volume of oxygen followed by room air breathing. In the study illustrated in FIG. 7, a few breaths of hypoxic gas were first administered to
decrease the subject=s baseline SaO2 followed by continuous 100% supplemental oxygen administration via a non-rebreather mask. In the study illustrated in FIG. 8, hypoxic gas was first administered followed by a pulse of 100% supplemental oxygen via a non-rebreather mask.
The results of the studies were reported as range, mean Vstandard deviation.
The measured parameters were reported along with R, correlation coefficient, and P- value, probability value. The median was the value at which half the measurements were greater than and half the values were less than the reported value. R is the correlation coefficient, a statistical value to describe how well the data are represented by an equation of a straight line. A group of values that form a perfect line have an R value of 1. A group of values that are randomly distributed have an R value of 0. The p value is a statistical representation of the probability that there is some relationship
11 between two variables, such as LFCT and cardiac output. The p value represents the probability of what is referred to as the null hypothesis, or that two variables under study are not related to one another. In the present studies, p was less than 0.001. In other words, there is greater than a 99.9% chance that the null hypothesis is not applicable and the two variables are related to one another.
The comparison of LFCT and Tb with cardiac output measured by the thermodilution method resulted in an LFCT range of 35.2-136.4 seconds, with mean
LFCT at 52.8V20.8 seconds and Tb range of 12.6-56.7 seconds with mean Tb of 21.0V9.1 seconds. The subjects= cardiac output as measured by thermodilution ranged
from 2.6 to 8.0 L/min with mean cardiac output of 5.1V1.3 L/min. The LFCT (sec)
inversely correlated in a linear fashion with thermodilution measured cardiac output
(R=0.76, p < .001) (FIG. 3). Furthermore, the inverse of Tb (sec 1) also correlated in a linear fashion with the cardiac output (R=0.72, p< .001) (FIG. 3).
Mean baseline oxygen saturation was 94.5%V2.2 with the median at 95%. Secondary to low signal to noise ratio in subjects with high baseline oxygen saturation, the subset of subjects with baseline oxygen saturation at or below the median (13 of 22
subjects), was analyzed separately and compared to those with baseline oxygen saturation greater than the median (9 of 22 subjects). Stronger correlation was observed among the measurements of LFCT with cardiac output in subjects with lower baseline oxygen saturation (R=0.87, p<0.001) (FIGs 4 and 5).
These studies demonstrate that measurement of oxygen Lung to Finger Circulation Time (LFCT) as well as its Buildup Time (Tb) are inversely proportional
to cardiac output as measured by a standard invasive technique. Measuring cardiac output according to either Lung to Finger Circulation Time (LFCT) or Buildup Time
12 (Tb) is safe due to the use of oxygen as the indicator and its noninvasive nature. Furthermore, these determinations are inexpensive and practical since they utilizes detection by oximeters, which are commonly found in the hospital and clinical settings. Other modifications of the present invention will occur to those skilled in the art subsequent to a review of the present application. These modifications and equivalents thereof are intended to be included within the scope of this invention.
13

Claims

CLAIMS What is claimed:
1. A method of determining cardiac output, comprising:
(A) administering a respiratory gas for inhalation into a living body at a first location; and
(B) determining circulation time (CT) at a second location as a measure of cardiac output.
2. The method of claim 1, wherein CT is time between administration of said respiratory gas and detecting of an increase peak in concentration of said gas at said second location.
3. The method of claim 1, comprising measuring oxygen saturation to establish a baseline oxygen saturation level.
4. The method of claim 1, wherein (A) comprises continuously administering an increased oxygen. 5. The method of claim 1, wherein (A) comprises administering an increased oxygen in pulses.
6. The method of claim 1, wherein (A) comprises administering a hypoxic gas to decrease a baseline saturated oxygen level and then continuously administering an increased oxygen. 7. The method of claim 1, wherein (A) comprises administering a hypoxic gas to decrease a baseline saturated oxygen level and then administering an increased oxygen in pulses.
8. The method of claim 1, further comprising calculating cardiac output as a function of CT.
14 9 The method of claim 1, comprising monitoring cardiac output according to said CT
10 The method of claim 10, comprising determining oxygen saturation of blood from said adsorption of optical radiation 11 The method of claim 2, further comprising detecting said increase peak in said gas by measuring adsorption of optical radiation per time through living tissue at a location respiratorily downstream from said first location to determine change in circulated oxygen concentration per time as a result of administration of said respiratory gas.
12 The method of claim 11, wherein said adsorption of optical radiation is measured by an oximeter that emits optical radiation into said tissue and detects optical radiation at an exit from said tissue
13 The method of claim 12, comprising generating a spectophotometric signal by means of said oximeter and deriving arterial hemoglobin oxygen saturation from said spectophotometric signal 14 A method of determining cardiac output, comprising-
(A) administering a respiratory gas for inhalation into a living body at a first location; and
(B) determining buildup time (Tb) at a second location as a measure of cardiac output. 15 The method of claim 14, wherein Tb is time between first detecting of an increase in said respiratory gas at said second location to detecting an increase peak in concentration of said gas at said second location.
16 The method of claim 14, further comprising calculating cardiac output as a function of Tb.
15
17. The method of claim 14, comprising measuring oxygen saturation to establish a baseline oxygen saturation level.
18. The method of claim 14, wherein (A) comprises continuously administering an increased oxygen. 19. The method of claim 14, wherein (A) comprises administering an increased oxygen in pulses.
20. The method of claim 14, wherein (A) comprises administering a hypoxic gas to decrease a baseline saturated oxygen level and then continuously administering an increased oxygen. 21. The method of claim 14, wherein (A) comprises administering a hypoxic gas to decrease a baseline saturated oxygen level and then administering an increased oxygen in pulses.
22. The method of claim 14, further comprising first detecting said gas and detecting said increase peak of said gas by measuring adsorption of optical radiation per time through living tissue at a location respiratorily downstream from said first location to determine change in circulated oxygen concentration per time as a result of administration of said respiratory gas.
23. The method of claim 22, comprising determining oxygen saturation of blood from said adsorption of optical radiation. 24. The method of claim 22, wherein said adsorption of optical radiation is measured by an oximeter that emits optical radiation into said tissue and detects optical radiation at an exit from said tissue..
16
25. The method of claim 24, comprising generating a spectophotometric signal by means of said oximeter and deriving arterial hemoglobin oxygen saturation from said spectophotometric signal
26. A system for determining cardiac output in a living body, comprising; (A) a source to administer a respiratory gas for inhalation into a living body at a first location;
(B) a device connected to said living body at a location respiratorily downstream from said first location for measuring oxygen saturation of blood by means of adsoφtion of optical radiation through living tissue; and (C) a processor that calculates circulation time (CT) or buildup time (Tb) from said device measurements to determine cardiac output.
27. The system of claim 26, wherein said device comprises a spectophotometric signal generator and said processor comprises a computer for deriving arterial hemoglobin oxygen saturation from a spectophotometric signal. 28. The system of claim 26, wherein said device comprises a finger or ear pulse probe connected to a pulse oximeter.
29. The system of claim 26, additionally comprising a graphics means to plot and display continuous oxygen saturation measurements against time.
30. The system of claim 26, additionally comprising an hypoxic gas source and a switch to change from said oxygen source to said hypoxic gas source.
17
PCT/US1999/008539 1998-04-20 1999-04-20 Determining cardiac output WO1999053834A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8229098P 1998-04-20 1998-04-20
US60/082,290 2014-11-20

Publications (1)

Publication Number Publication Date
WO1999053834A1 true WO1999053834A1 (en) 1999-10-28

Family

ID=22170272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/008539 WO1999053834A1 (en) 1998-04-20 1999-04-20 Determining cardiac output

Country Status (1)

Country Link
WO (1) WO1999053834A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6819950B2 (en) 2000-10-06 2004-11-16 Alexander K. Mills Method for noninvasive continuous determination of physiologic characteristics
US8398555B2 (en) 2008-09-10 2013-03-19 Covidien Lp System and method for detecting ventilatory instability
WO2013148180A1 (en) * 2012-03-27 2013-10-03 The University Of Vermont And State Agricultural College Non-invasive methods for determining cardiac output
US8596270B2 (en) 2009-08-20 2013-12-03 Covidien Lp Systems and methods for controlling a ventilator
US9180260B2 (en) 2013-08-30 2015-11-10 Covidien Lp Systems and methods for monitoring an injection procedure
JP2019166148A (en) * 2018-03-23 2019-10-03 富士ゼロックス株式会社 Biological information measurement device and biological information measurement program
JP2019166152A (en) * 2018-03-23 2019-10-03 国立大学法人九州大学 Biological information measurement device, and biological information measurement program
JP2019166145A (en) * 2018-03-23 2019-10-03 富士ゼロックス株式会社 Biological information measurement device and biological information measurement program
US10448851B2 (en) 2012-09-11 2019-10-22 Covidien Lp System and method for determining stroke volume of a patient
CN111432719A (en) * 2018-03-23 2020-07-17 富士施乐株式会社 Biological information measurement device, biological information measurement program, and storage medium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5299579A (en) * 1989-11-24 1994-04-05 Minco Ab Apparatus for examining a patient's pulmonary function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5299579A (en) * 1989-11-24 1994-04-05 Minco Ab Apparatus for examining a patient's pulmonary function

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6819950B2 (en) 2000-10-06 2004-11-16 Alexander K. Mills Method for noninvasive continuous determination of physiologic characteristics
US8398555B2 (en) 2008-09-10 2013-03-19 Covidien Lp System and method for detecting ventilatory instability
US8596270B2 (en) 2009-08-20 2013-12-03 Covidien Lp Systems and methods for controlling a ventilator
US9439577B2 (en) 2012-03-27 2016-09-13 The University Of Vermont And State Agricultural College Non-invasive methods for determining cardiac output
WO2013148180A1 (en) * 2012-03-27 2013-10-03 The University Of Vermont And State Agricultural College Non-invasive methods for determining cardiac output
US10448851B2 (en) 2012-09-11 2019-10-22 Covidien Lp System and method for determining stroke volume of a patient
US11445930B2 (en) 2012-09-11 2022-09-20 Covidien Lp System and method for determining stroke volume of a patient
US9180260B2 (en) 2013-08-30 2015-11-10 Covidien Lp Systems and methods for monitoring an injection procedure
JP2019166148A (en) * 2018-03-23 2019-10-03 富士ゼロックス株式会社 Biological information measurement device and biological information measurement program
JP2019166152A (en) * 2018-03-23 2019-10-03 国立大学法人九州大学 Biological information measurement device, and biological information measurement program
JP2019166145A (en) * 2018-03-23 2019-10-03 富士ゼロックス株式会社 Biological information measurement device and biological information measurement program
CN111432719A (en) * 2018-03-23 2020-07-17 富士施乐株式会社 Biological information measurement device, biological information measurement program, and storage medium
JP7119482B2 (en) 2018-03-23 2022-08-17 富士フイルムビジネスイノベーション株式会社 Biological information measuring device and biological information measuring program
CN111432719B (en) * 2018-03-23 2023-04-18 富士胶片商业创新有限公司 Biological information measurement device, biological information measurement method, and storage medium

Similar Documents

Publication Publication Date Title
US11179044B2 (en) Method of measuring cardiac related parameters non-invasively via the lung during spontaneous and controlled ventilation
Clark et al. Noninvasive Assessment of Blood Gases1-3
Kamat Pulse oximetry
Taylor et al. The current status of pulse oximetry: clinical value of continuous noninvasive oxygen saturation monitoring
US8613707B2 (en) System and method for monitoring cardiac output
US7611470B2 (en) Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution
Deckardt et al. Noninvasive arterial hemoglobin oxygen saturation versus transcutaneous oxygen tension monitoring in the preterm infant
Soubani Noninvasive monitoring of oxygen and carbon dioxide
US20080208019A1 (en) Modified Pulse Oximetry Technique For Measurement Of Oxygen Saturation In Arterial And Venous Blood
US20100191080A1 (en) Method for noninvasive continuous determination of physiologic characteristics
JP2005507298A (en) A non-invasive method for continuous measurement of physiological characteristics
Di Fiore Neonatal cardiorespiratory monitoring techniques
US7070569B2 (en) Non-invasive determination of conditions in the circulatory system of a subject
WO2000067634A2 (en) Airway-based cardiac output monitor and methods for using same
Mahler et al. Determination of cardiac output at rest and during exercise by carbon dioxide rebreathing method in obstructive airway disease
WO1999053834A1 (en) Determining cardiac output
Jørgensen et al. Limitations of forehead pulse oximetry
Bongard et al. Pulse oximetry and capnography in intensive and transitional care units.
Cho et al. Comparison of two commercially available near-infrared spectroscopy instruments for cerebral oximetry
Miller et al. A simple method for the continuous noninvasive estimate of cardiac output using the Maxima breathing system. A pilot study
Mathew et al. Noninvasive monitoring of gas exchange
Barrington et al. Pulse oximetry during hemorrhagic hypotension and cardiopulmonary resuscitation in the rabbit
Lynn et al. Pulse oximetry during cardiac catheterization in children with congenital heart disease
Thys et al. The pulse oximeter: A non-invasive monitor of oxygenation during thoracic surgery
Hieronymi et al. Respiratory monitoring and pulse oximetry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase